Melissa Badamo

Articles by Melissa Badamo

Melissa BadamoMyelodysplastic Syndromes | April 16, 2024
The average rate of progression for CHIP to MDS or AML is about 1% per year, Dr. Patel explained.
View More
Melissa BadamoPrint | April 16, 2024
Dr. Vose discusses how she became a hematologist, how she nurtures her artistic side outside of work, and more.
Kenneth Anderson, MDMyeloma | April 11, 2024
The “real revolution” in myeloma is in the immune therapies, Dr. Anderson said, such as bispecific T-cell engagers and ...
Shaikha Alqahtani, MDAcute Myeloid Leukemia | April 10, 2024
Around 45% of patients had a complete response after cladribine, and 31% proceeded to transplant.
Melissa BadamoAcute Myeloid Leukemia | April 9, 2024
The researchers found that CALM-AF10 leukemia cells grow slower after the SIX1 knockdown.
Melissa BadamoMyeloma | April 8, 2024
The overall response rate was 71%, and the most common side effects were CRS, neutropenia, and anemia.
This issue of Blood Cancers Today includes a feature on advancing CMML; an editor's message from Kami Maddocks, MD; and more.
Melissa BadamoTransplantation & Cellular Therapy | April 5, 2024
The investigators reviewed case reports of patients 20 years old and younger who underwent therapy for BPDCN.
Melissa BadamoMyelofibrosis | April 4, 2024
The primary endpoint was overall best response after blast-reduction therapy.
Melissa BadamoAcute Myeloid Leukemia | April 10, 2024
The conference has a lot of great sessions, including an untraditional keynote speaker, Dr. Hastings said.
Melissa BadamoAcute Myeloid Leukemia | April 1, 2024
The ORR was 64% in the frontline cohort and 46% in the relapsed or refractory cohort.
Melissa BadamoMyeloproliferative Neoplasms | March 29, 2024
Dr. Harrison discusses her current clinical research, building community with MPN Voice, and her journey into hematology.
Melissa BadamoChronic Lymphocytic Leukemia | March 29, 2024
In patients with CLL, zanubrutinib showed advantages in PFS and CR rates with "potentially improved" OS.
Melissa BadamoAggressive B-Cell Lymphoma | March 25, 2024
The approval was declined due to the enrollment status of the confirmatory trials.
Leah SherwoodMyelodysplastic Syndromes | March 25, 2024
The Leukemia and Lymphoma Society's CMML Initiative hopes for dedicated CMML trials and CMML-directed therapies.
Melissa BadamoMyeloma | March 22, 2024
The approval was based on results from the KarMMa-3 study, which compared ide-cel with standard combination regimens.
Melissa BadamoAcute Myeloid Leukemia | March 21, 2024
A significant number of patients receiving ivosidenib had reduced levels of voriconazole and posaconazole.
Melissa BadamoMyelodysplastic Syndromes | March 22, 2024
The case study included four patients with CMML who had KRAS mutations and a multitude of autoimmune diseases.
Melissa BadamoChronic Lymphocytic Leukemia | March 29, 2024
The CAR-T therapy was approved based on response rate and duration of response data from the TRANSCEND CLL 004 trial.
Douglas Tremblay, MDMyelodysplastic Syndromes | March 15, 2024
The study also explored the role of this combination in transitioning patients to HSCT.